Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where R.V. Hymas is active.

Publication


Featured researches published by R.V. Hymas.


Journal of Clinical Oncology | 2014

Dosimetric predictors of toxicity and cosmesis in women treated with hypofractionated whole-breast irradiation.

J.T. Dilworth; R.V. Hymas; M.S. Jawad; V.S. Mangona; Leonid Zamdborg; Jessica Wobb; A. Pietron; M. Wallace; Peter Y. Chen; I.S. Grills; Donald S. Brabbins

77 Background: Large breast volume (BV) and distance of separation (DoS) have historically served as exclusionary criteria for hypofractionated whole breast irradiation (H-WBI). We investigate dosimetric parameters impacting toxicity and cosmesis. METHODS 299 consecutive patients with T0-2,N0-1,M0 breast cancer were treated with H-WBI at a single institution from 2007-2013. 4,256 cGy were delivered in 16 fractions via tangent photon beams utilizing inverse planning, with objectives to limit the V105 to 15%, the V110 to 2%, and the V115% to <0.1%. 227 patients with available treatment planning information and at least 6 months of follow-up (FU) were analyzed. Dosimetric parameters were correlated with acute (≤6 months post-treatment) and chronic toxicity and overall cosmesis. Proportions of toxicity grade and cosmesis score were compared with chi-square or Fisher exact tests. RESULTS With a median FU of 2.7 years (range 0.4-6.6 years), there were no local or regional recurrences, 1 distant failure, and one in-field angiosarcoma. Rates of any acute and chronic grade 1/2/3 toxicity were 47%/32%/9% and 53%/22%/7%. Cosmesis (beyond 6 months) was reported as excellent, good, and fair in 45%, 55%, and <1% of patients. The V105 was the best predictor for cosmesis and chronic toxicity, with a V105≤10% being associated with better cosmesis (excellent vs fair/poor) and lower toxicity (grade 0 vs grade 1 vs grade 2/3) compared to a V105>10% (p=0.09 and 0.03, respectively). The mean DoS was 22 cm, with 22% and 3% of patients having a DoS greater than 25 cm and 28 cm. The mean BV was 1523 cc, with 19% and 5% having a BV greater than 2000 cc and 2500 cc. Neither a larger DoS nor a larger BV correlated with an inability to achieve a V105≤10% (p= 0.37 and p=0.13, respectively). Neither DoS nor BV predicted for worse acute toxicity, chronic toxicity, or cosmesis. CONCLUSIONS Minimizing the V110 and V115 and limiting the V105 to ≤10% are useful dosimetric objectives to achieve excellent or good cosmesis following H-WBI. Acceptable toxicity and excellent cosmesis are achievable in women with large DoS or BV, provided techniques to maximize dose homogeneity are employed.


International Journal of Radiation Oncology Biology Physics | 2013

Toxicity After Central Versus Peripheral Stereotactic Lung Radiation Therapy (SBRT): A Propensity Score Matched-Pair Analysis

A.M. Aneese; V.S. Mangona; R.V. Hymas; O. Marina; D. Ionascu; L.J. Gallardo; D. Yan; J.M. Robertson; I.S. Grills


International Journal of Radiation Oncology Biology Physics | 2013

Clinical Outcomes After Central Versus Peripheral Stereotactic Lung Radiation Therapy (SBRT): A Propensity Score Matched-Pair Analysis

V.S. Mangona; A.M. Aneese; O. Marina; R.V. Hymas; D. Stromberg; D. Ionascu; D. Yan; I.S. Grills


International Journal of Radiation Oncology Biology Physics | 2017

Operable Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Radiotherapy (SBRT) Compared to Surgical Lobectomy: Failure Patterns and Implications for Management

I.S. Grills; K.C. Lee; R.V. Hymas; H. Ye; K. Sura; M.C. Johnson; N. Abro; A. Caruso; E. Abbott; R.L. Deraniyagala; C.W. Stevens; R. Welsh


International Journal of Radiation Oncology Biology Physics | 2017

International Collaborative Propensity-Based Matched Pair Analysis of Operable Early Stage Lung Ancer Patients Treated with Stereotactic Body Radiation Therapy Compared to Resection: Differences in Recurrence and Survival with Prolonged Follow-Up

I.S. Grills; K.C. Lee; J. Belderbos; Andrew Hope; Meredith Giuliani; M. Guckenberger; Frederick Mantel; Maria Werner-Wasik; Heike Peulen; J.J. Sonke; D. Yan; R.V. Hymas; A. Caruso; N. Abro; M.C. Johnson; E. Abbott; H. Ye; R. Welsh


International Journal of Radiation Oncology Biology Physics | 2016

Multimodal Imaging (Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging) of a Murine Model of Radiation Pneumonitis (RP) Following Stereotactic Lung Treatment

R.V. Hymas; S.A. Krueger; Thomas Guerrero; I.S. Grills; Brian Marples


International Journal of Radiation Oncology Biology Physics | 2016

Improving the Efficacy of Pulsed Radiation Therapy Using DNA Repair Inhibitors: A Preclinical Study

Brian Marples; S.A. Krueger; T.G. Wilson; M.B. Dabjan; K.C. Lee; R.V. Hymas; George D. Wilson; Spencer J. Collis


International Journal of Radiation Oncology Biology Physics | 2015

Outcomes for Patients With Atypical and Anaplastic Meningioma Treated With Surgical Resection With or Without Radiation Therapy

R.V. Hymas; M.A. Taquee; I.S. Grills; Peter Y. Chen; D.J. Krauss; K. Marvin; H. Ye; J.T. Dilworth


International Journal of Radiation Oncology Biology Physics | 2014

Dosimetric Predictors of Toxicity and Cosmesis in Women Treated With Hypofractionated Whole-Breast Irradiation

R.V. Hymas; M.S. Jawad; V.S. Mangona; L. Zamdborg; Jessica Wobb; A. Pietron; M. Wallace; Peter Y. Chen; I.S. Grills; D.S. Brabbins; J.T. Dilworth


International Journal of Radiation Oncology Biology Physics | 2013

A Matched Pair Analysis of Stage I Non-Small Cell Lung Cancer Treated With Lobectomy, Stereotactic Radiation Therapy (SBRT), or Wedge Resection

R.V. Hymas; V.S. Mangona; R. Welsh; G. Chmielewski; A.M. Aneese; O. Marina; A.M. Baschnagel; B.R. Gustafson; R. Deraniyagala; I.S. Grills

Collaboration


Dive into the R.V. Hymas's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

H. Ye

Oakland University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge